Highlights Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Delayed Nasdaq Other stock markets 17:08:52 27/06/2024 BST			5-day change	1st Jan Change
3.462 ^USD	+0.33%		-8.43%	-73.12%

06-14	Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial	CI
05-15	Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial	06-14	CI
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)	05-15	CI
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data	05-07	CI
Sector Update: Health Care Stocks Ease in Afternoon Trading	04-18	MT
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU	04-18	MT
Top Premarket Decliners	04-16	MT
Moleculin Biotech Shares Rise Following Patent Announcement	03-27	MT
Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial	03-25	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Moleculin Biotech to Effect 1-For-15 Reverse Stock Split to Regain Compliance	03-19	MT
Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3	01-24	CI
Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months	11-13	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases	21/09/23	CI
Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin	18/09/23	CI
Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials	10/08/23	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Moleculin Biotech, Inc. Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials	22/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Highlights

Filters